Loading...
CRBP logo

Corbus Pharmaceuticals Holdings, Inc.NasdaqCM:CRBP Stock Report

Market Cap US$142.7m
Share Price
US$7.70
US$36.5
78.9% undervalued intrinsic discount
1Y-14.2%
7D4.3%
1D
Portfolio Value
​
View

Corbus Pharmaceuticals Holdings, Inc.

NasdaqCM:CRBP Stock Report

Market Cap: US$142.7m

Corbus Pharmaceuticals Holdings (CRBP) Stock Overview

A clinical stage company, develops and commercializes therapeutics for cancer and obesity. More details

CRBP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 76.72% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market


CRBP Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Corbus Pharmaceuticals Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Corbus Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$7.70
52 Week HighUS$20.56
52 Week LowUS$6.72
Beta2.59
1 Month Change-30.25%
3 Month Change-19.71%
1 Year Change-14.16%
3 Year Change-2.65%
5 Year Change-87.95%
Change since IPO-91.44%

Recent News & Updates

Analysis Article • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Recent updates

Analysis Article • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha
Analysis Article • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...
Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024. Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024. Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.
Analysis Article • Nov 19

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

CRBPUS BiotechsUS Market
7D4.3%-1.9%-4.1%
1Y-14.2%23.6%20.6%

Return vs Industry: CRBP underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: CRBP underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is CRBP's price volatile compared to industry and market?
CRBP volatility
CRBP Average Weekly Movement13.6%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: CRBP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CRBP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200936Yuval Cohenwww.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary

How do Corbus Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
CRBP fundamental statistics
Market capUS$142.66m
Earnings (TTM)-US$84.53m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.7x
P/E Ratio

Is CRBP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRBP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$74.27m
Gross Profit-US$74.27m
Other ExpensesUS$10.26m
Earnings-US$84.53m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-4.56
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CRBP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 13:03
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.
George ZavoicoB. Riley Securities, Inc.